Cancer

Antibodies for Cancer Researchbioxcell.com

Antibodies for Cancer Research
α-mouse 4-1BB (BP0169)

α-mouse VISTA (BP0310)

α-mouse CTLA-4 (BP0131)

α-mouse GITR (BP0063)

CD4+ T cells
Control

CD4+ T cells
Control

LOB12.3

Relative Cell Number

Relative Cell Number

DTA-1

VISTA (35 kDa)
CTLA-4 (30 kDa)

Purified VISTA

Log Fluorescence Intensity

Antigen

Reactivity

Purified CTLA-4

Application

Log Fluorescence Intensity

Clone

4-1BB (CD137)

mousein vivo activation of 4-1BB

LOB12.3

4-1BB (CD137)

mousein vivo and in vitro 4-1BB stimulation

3H3

InVivoMab InVivoPlus
CatalogCatalog
BE0169BP0169BE0239BP02394-1BB (CD137)

mousein vitro 4-1BB blockade, FC

17B5

BE02964-1BBL (CD137L)

mousein vivo 4-1BBL blockade

TKS-1

BE0110

B7-1 (CD80)

mousein vivo B7-1 blockade, Affinity chromatography

1G10

BE0134

BTLA (CD272)

mousein vivo BTLA stimulation, in vivo BTLA blockade

6A6BE0132

BTLA (CD272)

mousein vivo and in vitro stimulation of BTLA, FC

PK18.6

BE0153

BTLA (CD272)

mousein vivo BTLA blockade, in vitro T cell stimulation/activation, FC

PJ196

BE0196

CD19mousein vivo B cell depletion, in vivo CD19 neutralization, in vitro B cell negative selection, FC

1D3BE0150

CD19

human

FC, Functional assays, IF, Chimeric antigen receptor construction

4G7BE0281

CD20

mouse

in vivo B cell depletion, WB

MB20-11BE0356CD20

human/monkey

in vivo B cell depletion in hCD20 Tg mice, IHC-F, IP, FC

2H7BE0276

CD20

mouse

FC, WBAISB12

BE0302

CD24

mouse

in vivo administration, IHC-F, IHC-P, IF, FC

M1/69BE0360

CD27

mouse

in vivo CD27 stimulation, in vitro CD27 stimulation, IP, FC

RM27-3E5

BE0348

CD28

mouse

in vitro T cell stimulation/activation, in vivo CD28 blockade

37.51

BE0015-1

CD28

mouse

in vitro T cell stimulation/activation

PV-1

BE0015-5

CD28

human

in vitro T cell stimulation/activation

9.3

BE0248CD28

human/monkey

in vitro T cell stimulation/activation, FC, IHC-F, IP

CD28.2

BE0291

CD28

mouse

in vivo and in vitro T cell stimulation/activation

D665

BE0328

CD38

mouse

in vivo and in vitro CD38 stimulation, in vitro B cell activation, IFNIMR5BE0317

CD40

mousein vivo CD40 activation, in vitro B cell stimulation/activation

FGK4.5/FGK45

BE0016-2

BP0016-2

CD40L (CD154)

mousein vivo and in vitro blocking of CD40/CD40L signaling

MR-1

BE0017-1

BP0017-1

CD40L (CD154)

human/monkey

in vitro and in vivo blocking of CD40/CD40L signaling, IP, FC

5C8BE0292

CD44

mouse/humanin vivo CD44 neutralization

IM7BE0039
BE0262

CD44

humanin vivo CD44 blockade in xenografts, in vitro CD44 blockade, WB, IF

Hermes-1

CD47

humanin vitro CD47 neutralization, in vivo CD47 neutralization in human tumor xenograft models or humanized mice, FC

B6H12BE0019-1

CD47

human/mouse/rat

in vivo CD47 blockade, in vitro CD47 blockade, IFMIAP410

BE0283

CD47 (IAP)

mousein vivo CD47 blockade, in vitro CD47 blockade, IFMIAP301

BE0270

CD69

mouse

in vivo down-regulation of CD69 expression, Functional assays

CD69.2.2

BE0330

CD70

mouse

in vivo and in vitro CD70 blockade, FC

FR70

BE0022

CD71 (TfR)

humanWB, IP, FC

5E9C11BE0343

CD71 (TfR1)

mousein vivo depletion of CD71+ cells

R17 217.1.3

BE0175

CD71 (TfR1)

mousein vivo depletion of CD71+ cells, IF, IHC-F, WB

8D3

BE0329CD71 (TfR1)

rat/mouse

Targeted drug delivery to the brain, IHC-F, FC

OX-26

BE0331

CD73

mouse

in vivo CD73 blockade

TY/23

BE0209CD80 (B7-1)

mouse

in vivo CD80 blockade, FC

16-10A1

BE0024

CD86 (B7-2)

mousein vivo CD86 blockade, FC

GL-1

BE0025

CD96

mouse

in vivo and in vitro CD96 blocking, FC

3.3

BE0337

CD103

mouse

in vivo CD103 neutralization, IF, FC

M290

BE0026

CD172a (SIRPα)mousein vivo and in vitro SIRPα blocking, WB, IP, FC

P84

BE0322

CD209b (SIGN-R1)

mousein vivo SIGN-R1 blockade, IHC-F, WB, FC

22D1

BE0220CD276 (B7-H3)

mousein vivo B7-H3 blockade, FC

MJ18

BE0124

CD314 (NKG2D)

mouse

in vivo and in vitro NKG2D blockade, FC

CX5BE0334

CD326 (EpCAM)

mouse

IHC-F, IF, FC, WB

G8.8

BE0346c-Kit (CD117)

mouse

FC, IF, IHC

2B8

BE0280c-Kit (CD117)

mousein vivo mast cell depletion, in vivo c-Kit+ cell depletion, in vitro c-Kit neutralization, IP, FC

ACK2BE0293c-myc

human

WB, ELISA, FC

9E10

BE0238

CLEC9A (CD370)

mousein vivo Ag targeting to CLEC9A+ DCs, WB, ELISA, IP, IF, FC

7H11BE0305

CSF1R (CD115)

mousein vivo macrophage depletion, in vitro CSF-R1 neutralization, in vivo monocyte depletion, FC

AFS98

BE0213

IF Immunofluorescence | IHC-F Immunohistochemistry (frozen) | IHC-P Immunohistochemistry (paraffin) | WB Western blot | IP Immunoprecipitation

BP0283BP0213α-mouse PD-1 (BP0146)

InVivoMab vs. InVivoPlus

α-mouse PD-L1 (BP0101)

InVivoMabInVivoPlus> 95%> 95%< 2EU/mg< 1EU/mg

purity levelprotein aggregates validated at ≤ 5%
PD-L1 (45 kDa)
PD-1 (45 kDa)

azide and carrier protein freeendotoxin concentration
validated by immunoblot, FC, or ELISA
screened for murine pathogens

Purified PD-1

Antigen

Reactivity

Purified PD-L1

available in bulk quantities

Application

Clone

InVivoMab InVivoPlus
CatalogCatalog

CSF1R (CD115)

humanin vitro CSF1R neutralization, IHC-P, Functional assays, FC

2-4A5-4

CTLA-4 (CD152)

mousein vivo and in vitro CTLA-4 neutralization, FC

UC10-4F10-11BE0032BP0032CTLA-4 (CD152)

mousein vivo and in vitro CTLA-4 neutralization

9H10BE0131

BP0131BP0164

BE0347CTLA-4 (CD152)

mousein vivo CTLA-4 neutralization

9D9BE0164

CTLA-4 (CD152)

humanin vitro CTLA-4 neutralization, FC

BN13

BE0190DR5 (CD262)

mousein vivo and in vitro induction TRAIL-mediated apoptosis

MD5-1

BE0161

EGFR

human

in vitro EGFR blockade, in vivo EGFR blockade in xenografts, WB, Functional assays

225BE0278

EGFR

human

in vitro EGFR blockade, in vivo EGFR blockade in xenografts, WB, Functional assays, IP, IHC-P, IF, FC

528

BE0279

EphA2

human

IHC-P, IP, Functional assay

B2D6BE0341

E-Cadherin (CD324)

mousein vivo E-Cadherin neutralization, in vitro E-Cadherin neutralization, IF, IP, WB

DECMA-1

BE0352E-selectin (CD62E)

mouse

in vivo E-selectin blockade, in vitro E-selectin blockade, IHC-F

9A9

BE0294

FasL (CD178)

mousein vivo and in vitro FasL blockade, Functional assay, IHC-P, FC

MFL3

BE0319FGL-1

mousein vivo and in vitro FGL-1 blockade, FC, IHC-P

177R4BE0332

Galectin-9

mouse

in vivo and in vitro Galectin-9 blockade

RG9-1

BE0218

GITR

mouse

in vivo GITR stimulation

DTA-1BE0063

GM-CSFmousein vivo and in vitro GM-CSF neutralization, FC

MP1-22E9BE0259HER2 (neu)human/rat

in vivo and in vitro HER2/neu inhibition, IP, IF, FC

7.16.4

BE0277

ICOS

mouse

in vivo blocking of ICOS/ICOSL signaling, FC

7E.17G9BE0059

ICOSL (CD275)

mousein vivo ICOSL neutralization

HK5.3BE0028

IL-7Rα (CD127)

mousein vivo blocking of IL-7Rα signaling, FC

A7R34

BE0065

IL-17Fmousein vivo IL-17F neutralization

MM17F8F5.1A9BE0303

IL-27 p28

mouse

in vivo and in vitro IL-27 p28 neutralization, FC

MM27.7B1

BE0326

Jagged2

mouse

in vivo Jagged 2 neutralization

HMJ2-1

BE0125

LAG-3

mouse

in vivo and in vitro LAG-3 neutralization, FC

C9B7W

BE0174

LPAM-1 (Integrin α4ß7)

mouse

in vivo Integrin α4ß7 neutralization, FC

DATK32BE0034

LRP1 (CD91)

mouse/human/rat

WB, IF, IP

11H4BE0333

Ly6G

mouse

in vivo neutrophil depletion, in vivo MDSC depletion, IF, IHC-P, IHC-F, FC

1A8

BE0075-1

Ly6G/Ly6C (Gr-1)

mousein vivo neutrophil depletion, IHC-P, IHC-F, IF, FC

NIMP-R14

BE0320

Ly6G/Ly6C (Gr-1)

mousein vivo depletion of Gr-1+ myeloid cells, FC, IHC-P, IHC-F

RB6-8C5

BE0075MAGEC2 (CT10)

human

IHC-P, IF, WB

LX-CT10.5

BE0335
BE0340

MDR-1 (CD243)

human/monkey

in vivo MDR-1 blocking/depletion in xenogeneic murine tumor models, in vitro MDR-1 blocking, IHC-P

UIC2

MUC1 (CD227)

humanin vivo administration in mouse xenograft models, IHC-P, IF, in vitro cell cytotoxicity assay,WB

C595 (NCRC48) BE0336

NKG2A/C/E

mouse

in vivo and in vitro NKG2A blockade, IHC-F, FC

20D5BE0321

NKG2D

mouse

in vivo NKG2D blockade

HMG2D

BE0111BP0063BP0174

BP0075-1
BP0076

PD-1 (CD279)

mousein vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization

J43

BE0033-2

BP0033-3

PD-1 (CD279)

mousein vivo blocking of PD-1/PD-L signaling

RMP1-14BE0146BP0146

PD-1 (CD279)

humanin vitro PD-1 neutralization, in vivo PD-1 blockade in humanized mice

J116

BE0188

PD-1 (CD279)

humanin vivo PD-1 blockade in humanized mice, FC

J110

BE0193PD-1 (CD279)

mousein vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, IHC-F, FC, WB

29F.1A12

BE0273BP0273

PD-L1 (B7-H1)

mousein vivo PD-L1 blockade, IF, IHC-F, FC

10F.9G2

BE0101BP0101

PD-L1 (B7-H1)

humanin vitro PD-L1 blockade, Functional assays, IHC-F, FC

29E.2A3

BE0285

PD-L2 (B7-DC)mousein vivo and in vitro PD-L2 blockade, IHC-F, FC

TY25

BE0112RANKL (CD254)

mousein vivo RANKL blockade

IK22/5

BE0191

TIM-1 (CD365)

mousein vivo TIM-1 neutralization

RMT1-10BE0113

TIM-1 (CD365)

mousein vivo and in vitro TIM-1 blockade

3D10BE0314TIM-3 (CD366)

mousein vivo TIM-3 neutralization, in vitro TIM-3 blocking, FC

RMT3-23

BE0115TNFαmouse/rat/rabbit

in vivo TNFα neutralization, FC

TN3-19.12

BE0244BP0115VEGFR-2

mouse

in vivo blocking of VEGF/VEGFR-2 signaling, in vitro blocking of VEGFR signaling

DC101

BE0060BP0061

VISTA

mouse

in vivo and in vitro blocking of VISTA signaling, FC

13F3

BE0310BP0310VLDL-R

mouse/rat/bovine

WB

IgG-6A6

BE0345| FC Flow cytometry (requires flurochrome conjugation)

Antibodies for in vivo research since 1997.

For over 20 years, scientists have trusted Bio X Cell as their go-to source for in vivo functional grade antibodies.
This is reflected in over 15,000 peer-reviewed publications citing Bio X Cell products. We understand thisresponsibility is of paramount importance and remain committed to producing antibodies of unparalleled quality
and consistency, enabling our partners around the globe to accelerate research and discoveries.

Bio X Cellbioxcell.com | 1.866.787.3444
customerservice@bioxcell.com
Conditions: For Research Use Only. Not for use in diagnostic or theraputic procedures. Not for resale.
Bio X Cell, Bio X Cell Logo and all other trademarks are the property of Bio X Cell. © Bio X Cell 2021